Roche's Billion-Dollar Deal with Alnylam for Hypertension Drug
Roche's $3 billion deal with Alnylam for the rights to a hypertension treatment demonstrates a renewed interest from large pharmaceutical companies in developing long-acting heart drugs, as the cardiovascular disease market has been overshadowed by cancer and other diseases.